Aspira Women's Health Inc...

AI Score

0

Unlock

0.58
-0.04 (-6.19%)
At close: Jan 14, 2025, 3:59 PM
0.58
-0.16%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 0.47
Market Cap 10.13M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.15
PE Ratio (ttm) -0.5
Forward PE n/a
Analyst Buy
Ask 0.62
Volume 55,221
Avg. Volume (20D) 103,768
Open 0.62
Previous Close 0.62
Day's Range 0.57 - 0.62
52-Week Range 0.57 - 5.65
Beta undefined

About AWH

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service fo...

Sector Healthcare
IPO Date Oct 2, 2000
Employees 64
Stock Exchange NASDAQ
Ticker Symbol AWH

Analyst Forecast

According to 2 analyst ratings, the average rating for AWH stock is "Buy." The 12-month stock price forecast is $4.4, which is an increase of 661.51% from the latest price.

Buy 50.00%
Hold 50.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Aspira Women's Health Inc. is scheduled to release its earnings on Mar 27, 2025, during market hours.
Analysts project revenue of $2.40M, reflecting a 12.68% YoY growth and earnings per share of -0.22, making a -26.67% decrease YoY.
6 months ago · Source
+7.63%
Aspira Women's Health shares are trading higher af... Unlock content with Pro Subscription
6 months ago · Source
+4.04%
Aspira Women's Health shares are trading higher. The company announced a private placement equity financing of $1.935 million.